The reduction in T1DM mortality likely stems from advancements in insulin therapy, continuous glucose monitoring, and structured patient education, which have improved glycemic control and reduced acute complications like diabetic ketoacidosis (7). The gene discussed is INS; the disease is diabetic ketoacidosis.